Beam Therapeutics

Beam Therapeutics, Inc. develops and commercializes DNA base editing technologies for the treatment of human disease. Its licensed technology platform, which includes access to base editing technologies and associated technologies that enhance the scope of base editing. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Beam Therapeutics excels in base editing therapies, poised for growth

Beam Therapeutics showcased strong performance in trials and technology development, positioning itself as a leader in base editing therapies.
While facing challenges in clinical translation and regulatory landscapes, Beam's focus on innovative solutions presents growth opportunities in gene editing.
Overall, Beam's financial strength, promising data, and strategic vision offer a solid foundation for future success in the biotech industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.

The biotech will use its one-time "base-editing" genetic treatment to alleviate sickle-cell disease.

Beam Gets FDA Nod for First Gene-Editing Trial

CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Maraganore, Ph.D., founding chief executive officer and director of Alnylam Pharmaceuticals, has joined the company's board of directors.

Beam Therapeutics Appoints Healthcare Industry Leader John Maraganore, Ph.D., to its Board of Directors

BEAM-101 IND Cleared by FDA for Evaluation as a Treatment for Sickle Cell Disease

Beam Therapeutics Provides Business and Pipeline Updates and Reports Third Quarter 2021 Financial Results

Preclinical Data Demonstrates that BEAM-102 Makassar Base Editing Converts Sickle Hemoglobin to Functional Hemoglobin for Potential Treatment of Sickle Cell Disease

Beam Therapeutics Announces Upcoming Preclinical Data Presentations at the American Society of Hematology Annual Meeting

Beam Therapeutics Inc. (BEAM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Beam Therapeutics Inc. (BEAM) to Report a Decline in Earnings: What to Look Out for

CRISPR Therapeutics

Teladoc

These stocks are risky, though, and ideally suited for aggressive investors.

3 Stocks Cathie Wood Is Buying That You Might Want to Consider Too

CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Jefferies Gene Therapy/Editing Summit on Wednesday, October 27, 2021 at 4:00 p.m. ET.

Beam Therapeutics to Participate in the Jefferies Gene Therapy/Editing Summit

Sana Biotechnology

Sana Biotechnology Inc (NASDAQ: SANA) has secured non-exclusive commercial rights to Beam Therapeutics Inc's (NASDAQ: BEAM) CRISPR Cas12b nuclease system for certain ex vivo engineered cell therapy programs. The license does not include any rights to base editing using Cas12b, which remains at Beam.

Sana Obtains License To Beam Therapeutics' CRISPR Cas12b Gene Editing Technology

Findings Show Base Editing Leads to Elimination of Disease Phenotype in an In Vivo Model Findings Show Base Editing Leads to Elimination of Disease Phenotype in an In Vivo Model

Beam Therapeutics Announces Preclinical Data Highlighting Base Editing Approach to Correct a Glycogen Storage Disease Type Ia Disease-Causing Mutation

Allogene Therapeutics Inc

Intellia Therapeutics

A key gene-editing readout had Cathie Wood shuffling her portfolio.

Why Shares of Allogene Therapeutics, Beam Therapeutics, Intellia Therapeutics, and Schrödinger Are Volatile This Week

Ginkgo Bioworks Holdings

Signify Health

All three of these growth stocks have been tumbling, but that doesn't frighten off ARK Invest's top stock picker.

Cathie Wood Goes Dumpster Diving: 3 Sagging Stocks She Just Bought

Matterport

The disruptive potential for these companies is huge.

Got $500? 3 Game-Changing Stocks to Buy Right Now

Just as next-gen sequencing (NGS) tech kickstarted a multi-hundred-billion-dollar Genomic Revolution that resulted in multiple 10X winners in the 2010s, next-gen protein sequencing (NGPS) tech will kickstart an equally large Proteomic Revolution that will result in multiple 10X winners in the 2020s. The post Step Aside, Genomic Revolution.

Step Aside, Genomic Revolution. Welcome, the Proteomic Revolution!

Gene-editing companies are fighting for their share in a future multi-trillion dollar market. BEAM has a great management team, the best gene-editing technology, and follows a very smart platform licensing approach and is therefore positioned to dominated that market.

Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio

CAMBRIDGE, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present preclinical data from its multiplex edited allogeneic CAR T research targeting CD5-positive hematologic malignancies. The data will be presented in a poster titled “CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell malignancies” at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting. The conference is being held Nov. 10-14, 2021.

Beam Therapeutics to Present Preclinical Data Highlighting Potential of CAR T Multiplex Base Editing Approach Targeting CD5 at 2021 SITC Annual Meeting

CAMBRIDGE, Mass., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the Chardan Virtual 5th Annual Genetic Medicines Conference on Tuesday, Oct. 5, 2021 at 8:00 a.m. ET.

Beam Therapeutics to Participate in the Chardan Virtual 5th Annual Genetic Medicines Conference

Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce viral markers, including hepatitis B surface antigen (HBsAg) expression, and prevent viral rebound of hepatitis B virus (HBV) in in vitro models.

Beam Therapeutics' Base Editors Show Encouraging Preclinical Action In HBV Infection

Data to be Presented During an Oral Presentation at the 2021 International HBV Meeting Data to be Presented During an Oral Presentation at the 2021 International HBV Meeting

Beam Therapeutics Announces Preclinical Data Highlighting Potential of Base Editors to Target Disease Drivers of Chronic Hepatitis B Infection

Beam Therapeutics Inc (NASDAQ: BEAM) has announced new preclinical data for novel lipid nanoparticle (LNP) formulations for in vivo liver editing.  The Company says that continued optimization of LNPs has led to a substantial increase in liver editing potency, which is believed to be a clinically relevant dose for its lead LNP program, which will be finalized later this year.

Beam Therapeutics' Formulated LNP Show Tolerance, Early Storage Stability In Animal Studies

CAMBRIDGE, Mass., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced new preclinical data highlighting advancements with the company's approach to developing novel lipid nanoparticle (LNP) formulations for in vivo liver editing. In addition, the company reported initial in vivo data demonstrating its delivery capabilities to tissues outside of the liver. The data will be presented today, September 23, 2021, from 11:15 – 11:45 a.m. ET at the TIDES USA Oligonucleotide & Peptide Therapeutics Conference (TIDES 2021) in a presentation titled “Optimization of LNP for in vivo base editing.”

Beam Therapeutics Announces Updated Preclinical Data Highlighting Optimized LNP Delivery Approaches for In Vivo Base Editing to the Liver and Other Tissues

Editas Medicine

Vertex Pharmaceuticals

Wood is following an important strategy with gene-editing stocks.

Why Cathie Wood Is Buying 2 Gene-Editing Stocks but Selling Another

bluebird bio

Cellectis SA

Regeneron Pharmaceuticals

Gene editing stocks will take off as the underlying tech moves from fiction to fact and companies put their products on the market. The post 7 Gene Editing Stocks Promising to Change our DNA appeared first on InvestorPlace.

7 Gene Editing Stocks Promising to Change our DNA

One biotech could have the inside track to profit from a major achievement in CRISPR gene editing.

Could a Recent Gene Editing Breakthrough Make This Cathie Wood Stock a Buy?

CAMBRIDGE, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Wells Fargo Virtual Healthcare Conference on Friday, Sept. 10, 2021 at 9:20 a.m. ET.

Beam Therapeutics to Participate in the 2021 Wells Fargo Virtual Healthcare Conference

Illumina

Thanks to one small protein sequencing startup, we're entering a new era of proteomics via NGPS technologies that will enable massively parallel protein sequencing. The post Forget About the Genomic Revolution, the Proteomic Revolution Is Coming appeared first on InvestorPlace.

News for Beam Therapeutics Stock (BEAM)